Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: GlobeNewswire
Converts existing ILUVIEN profit share arrangement to royalty agreementNo upfront cash paymentAlimera Sciences plans to file ILUVIEN for posterior uveitis indication in 17 EU countries within 8 monthspSivida to withdraw centralized EU application for posterior uveitis ATLANTA, July 10, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it secured the rights to pursue posterior uveitis, a secondary indication for ILUVIEN, in the European Union (EU), the Middle East and Africa. Alimera secured the rights by signing a Second Amended and Restated Collaboration Agreement (the New Collaboration Agreement) with pSivida, US, Inc. (pSivida), a subsidiary of pSivida Corporation (NASDAQ:PSDV). The New Collaboration Agreement amends and restates the previous agreement entered into between the parties. Under the previous agreement, Alimera held the worldwid
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network [Yahoo! Finance]Yahoo! Finance
- Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkGlobeNewswire
ALIM
Earnings
- 3/7/24 - Miss
ALIM
Sec Filings
- 3/13/24 - Form 4
- 3/13/24 - Form 4
- 3/13/24 - Form 4
- ALIM's page on the SEC website